A Mutation Is Not a Destiny: Why the Future of Cancer Detection Lies in Metabolism

An RMDM Commentary

For decades, the story of cancer has been told as a story of mutations. Find the faulty gene, the thinking went, and you find the cancer. It is a compelling narrative, and it has driven an era of extraordinary genomic discovery. But it carries a quiet assumption that is now being challenged: that a cancer-causing mutation is, in itself, a sentence.

A growing body of evidence suggests otherwise. Carrying an oncogenic mutation does not mean cancer will follow. Whether a mutated cell remains harmless or progresses towards malignancy depends on far more than the mutation alone. It depends on the cell’s environment, on how cells communicate with one another, and, crucially, on the metabolic state of the cell itself.

This is not a minor refinement. It reshapes how we should think about detecting cancer early, and it sits at the very heart of what RMDM does.

 

The paradox of the humble mole

Few examples illustrate this better than the ordinary mole.

Most moles form through a mutation in a gene called BRAF. This is not a trivial mutation. BRAF is the single most commonly mutated gene in melanoma, one of the most dangerous skin cancers. And yet the overwhelming majority of moles never become melanoma. They appear, they grow to a certain size, and then they simply stop.

Why?

For years, the accepted explanation was “oncogene-induced senescence.” The idea was that the BRAF mutation itself triggered each cell to enter a kind of premature ageing, shutting down its own ability to divide. The mutation caused the problem, and the mutation, in effect, solved it.

It was a neat theory. It was also, it now appears, incomplete.

 

What the science revealed

A landmark study by Ruiz-Vega and colleagues, published in eLife, put this long-held assumption to the test. Using single-cell analysis and mathematical modelling of moles in a laboratory model, the researchers found no convincing evidence that the arrested cells were actually senescent. By the measures used to define ageing cells, mole cells looked no more senescent than ordinary skin cells around them.

Instead, the data pointed to something more sophisticated. The cells were not shutting down individually in response to their mutation. They were acting collectively, sensing their own overgrowth and signalling to one another to stop. This is the same kind of feedback that healthy tissues use to maintain a constant size. In other words, the mole stops growing not because each cell independently ages, but because the cells cooperate to hold themselves in check.

The finding has recently drawn renewed attention, revisited in 2026 by Nature Reviews Cancer, because it speaks to a broader shift in how cancer is understood. The question is no longer only “which mutation is present?” but “what allows a mutated cell to remain safe, and what happens when that safety fails?”

This is where the story becomes directly relevant to detection.

If a mutation alone does not determine cancer, then the decisive events lie elsewhere: in the biological state of the cell, and above all in its metabolism. Long before a tumour forms, before there is anything to see on a scan, a transformed cell begins to change how it produces energy. It shifts its metabolism to fuel rapid division, to invade, and to evade the body’s controls.

That metabolic shift is not a side effect of cancer. It is one of its earliest and most fundamental features. And it is measurable.

This is the principle on which RMDM’s approach is built. Our focus is not on cataloguing mutations that a cell might merely carry. It is on reading the metabolic state that reveals whether a cell has crossed the line from controlled to dangerous.

At the centre of this metabolic reading is TKTL1, an enzyme associated with the metabolic reprogramming that characterises malignant progression. When cells move away from the safe, cooperative, controlled state and towards the aggressive metabolism of cancer, TKTL1 activity reflects that change.

This matters because it offers a fundamentally different vantage point. A mutation tells you a cell could become cancerous. A metabolic signal tells you something about whether that potential is being realised. It shifts the question from predisposition to activity, from what might happen to what is happening.

PanTum Detect, RMDM’s blood-based early detection test, builds on this by measuring TKTL1 together with a second biomarker, Apo10 (DNaseX), which reflects disrupted cell death and accelerated proliferation. Together, these two markers read the metabolic behaviour of cells across many tumour types, from a single standard blood draw, acting as a first-line filter that identifies who may need further investigation and who does not.

The lesson of the mole is a hopeful one. It tells us that the body has powerful mechanisms for keeping transformed cells in check, and that cancer is not the automatic consequence of a single genetic error. It is the result of those mechanisms failing, and of a cell’s metabolism tipping towards malignancy.

If that is where cancer truly begins, then that is where detection should begin too. Not by waiting for a tumour to announce itself. Not by treating a mutation as a foregone conclusion. But by reading the metabolic signals that reveal, at the earliest possible moment, when a cell has begun to change.

Understanding what allows a mutated cell to stay harmless, and what happens when it does not, is one of the most important questions in cancer biology. It is also, for RMDM, the foundation of everything we do.

We do not wait for cancer to show itself. We detect it where it begins.

 

 

References

Ruiz-Vega R. et al., “Dynamics of nevus development implicate cell cooperation in the growth arrest of transformed melanocytes”, eLife, 2020.

Rodríguez-Lelis V. and Gómez-Schiavon M., “Avoiding cancer through collective behaviour”, Nature Reviews Cancer, 2026.